All News

podcast logo

RheumNow Podcast – Lupus Delights (9.18.20)

d Jack Cush, MD

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com:

Read Article
COVID infection mask

COVID-19 Risks in Pregnant Women

d Jack Cush, MD

There has been little science or evidence regarding the effects of COVID-19 infection on pregnancy and vice versa; and now the recent MMWR addresses the subject with two new reports

Read Article
gout.erosivehand.jpg

Methotrexate-Pegloticase Combination in Refractory Gout - MIRROR Study

d Jack Cush, MD

The MIRROR study, an open-label pilot trial in refractory, uncontrolled gout patients, showed that pegloticase given in combination with methotrexate was safe and effective and maintained responses for 6 months after initiation. 

Read Article
lupus.GN_.jpg

Belimumab Effective in Lupus Nephritis

d Jack Cush, MD

Dr. Rich Furie has lead a group of investIgators in reporting the significant efficacy of intravenous belimumab when added to standard of care induction therapy in patients with active lupus nephritis. This phase 3, 2-year study included 448 systemic lupus erythematosus patients with biopsy proven lupus nephritis (class III or IV +/- V) patients who required induction therapy and have a UPCR ≥1 g/g. 

Read Article
hip.fracture.jpg

Has the Risk of Hip Fracture Changed over Time?

d Jack Cush, MD

Data from the Framingham Heart Study has shown that hip fracture incidence has decreased over time, probably resulting from improved lifestyle changes (less smoking and heavy drinking). 

Read Article
pills-384846_640%20%281%29.jpg

NSAIDs Shows No Advantage over CBT in Knee Osteoarthritis

d Jack Cush, MD

JAMA Internal Medicine reports on a controlled clinical trial of knee osteoarthritis patients wherein meloxicam responses were not significantly or clinically superior to placebo or CBT (after placebo).

Read Article
Thank you all who participated in the survey. Here are some of our results #Covid_19 #rheumatology https://t.co/55ETf6kK6T

Links:

Bella Mehta bella_mehta ( View Tweet)

Dr. S. Louis “Lou” Bridges, Jr. (@HSS_PIC) shares what led him to HSS and what he hopes to do as the Chief of the Division of Rheumatology. For more about Dr. Bridges visit https://t.co/oNiQxlLFeP. https://t.co/2vcLwUZJYQ

Links:

Hosp Special Surgery HSpecialSurgery ( View Tweet)
"It’s a very difficult transition for providers to care for patients without a physical exam." #rheumatology #telemedicine @DartmouthHitch https://t.co/ZSHmVqXDaT

Links:

HCPLive MDMagazine ( View Tweet)

The RheumNow podcast is up! Lupus delights - Lupus & Diet, Drug induced lupus & brand new biologics for SLE. Good news on immunosuppressives, colchicine and baricitinib in COVID-19 patients. . Watch it here https://t.co/Ymsd3eXN5d or listen to the podcast https://t.co/20FOr3qu3X

Links:

Dr. John Cush RheumNow ( View Tweet)

Lupus Delights https://t.co/20FOr3qu3X https://t.co/AdRoaLDAmt

Links:

Dr. John Cush RheumNow ( View Tweet)
Doximity's 2020 State of Telemedicine report shows the top 10 specialties using telemedicine: 1. Endocrinology; 2. Rheumatology; 3. Gastroenterology, followed by Nephrology Cardiology GU Neurology Geriatrics Heme/onc Pulmonology https://t.co/J4Dt24ZlYg

Links:

Dr. John Cush RheumNow ( View Tweet)

Nurses' Health Study (79,568 women) examined the role of diet in 194 incident SLE cases and showed that diets (DASH, Meditteranean, antiinflammatory & healthy diets) had no significant effect of dietary quality on SLE risk https://t.co/JAFirjt0O8

Links:

Dr. John Cush RheumNow ( View Tweet)

NEJM report of 2 SLE pts treated w/ Daratumumab (anti-CD38) to deplete plasma cells a life-threatening refractory SLE. Clinical improvement associated w/ depletion of plasma cells, reduced IFN type I activity, down-regulation of T-cell transcripts https://t.co/K0fwpEHS81

Links:

Dr. John Cush RheumNow ( View Tweet)

COPDGene study of 361 DISH pts shows DISH carrieds a higher risk of coronary artery disease (OR 1.37 [1.05-1.78] (p=0.019), as measured by coronary calcium scores: 8.8% had CAC = 0; 12.8% CAC1-100; 20.0% CAC100-400 and 24.7% had a CAC>400. https://t.co/av1O907izH

Links:

Dr. John Cush RheumNow ( View Tweet)

Retrospective cohort study of 213 IMID patients, 36.2% tested positive for COVID-19, who had no greater risk of hospitalized or ventilation and immunosuppressive use was not shown to worsened the course of disease (TNFi decreased risk of hospitalization) https://t.co/gmIXDJkLCt

Links:

Dr. John Cush RheumNow ( View Tweet)

Taiwan National Health population study of 650 SLE and non-SLE controls undergoing hip replacement. SLE did not incr risk of early prosthetic infx, but did incr risk of late superficial wound infection (11.4% vs. 5.5%, P = 0.01; HR = 2.37) https://t.co/ZRMB23XLCk

Links:

Dr. John Cush RheumNow ( View Tweet)

Uncontrolled retrospective observational study of 31 RA-ILD DMARD refractory pts treated with RTX showed RTX to reverse the PFTs decline (∆%pFVC +8.06%; ∆%pDLCO +12.7%) while reducing median prednisone dose at 1 yr. @32 mos, 74% still on RTX. https://t.co/AVQCm2MpDk

Links:

Dr. John Cush RheumNow ( View Tweet)

Baricitinib in combo with Remdesivir reduces time to recovery in COVID-19 hospitalized pts in NIH-run ACTT-2 Trial w/ >1000 pts randomized to recv 4-mg baricitinib plus remdesivir versus remdesivir alone. Other baricitinib-COVID trials are in progress https://t.co/J87Ypeb4mn

Links:

Dr. John Cush RheumNow ( View Tweet)

Proof-of-concept study colchicine use in the context of COVID-19 infection leads to better survival. 140 consecutive COVID inpatients were Rx w/ standard of care +/- Colchicine. Survival rate @21d was better w/ colchicine (84% vs 64%;p=0.001). https://t.co/OzYd7pZ2ys

Links:

Dr. John Cush RheumNow ( View Tweet)

×